The American journal of psychiatry
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia. ⋯ Long-acting injectable risperidone was efficacious and well tolerated and provides both clinicians and patients with a new mode of treatment that can improve the outcome of long-term therapy.